about
Combined modality therapy for thoracic and head and neck cancers: a review of updated literature based on a consensus meeting.The Pocketable Electronic Devices in Radiation Oncology (PEDRO) Project: How the Use of Tools in Medical Decision Making is Changing?Postmastectomy radiotherapy for locally advanced breast cancer receiving neoadjuvant chemotherapy.Gamma Knife Radiosurgery in the management of single and multiple brain metastases.Adjuvant radiotherapy for a prostate cancer after renal transplantation and review of the literature.Management of inflammatory breast cancer: focus on radiotherapy with an evidence-based approach.Simultaneous integrated boost-intensity-modulated radiotherapy in head and neck cancer.Hypofractionation in prostate cancer: radiobiological basis and clinical appliance.A PPAR-gamma agonist attenuates pulmonary injury induced by irradiation in a murine model.Complete response in metastatic renal cell carcinoma after radiotherapy and everolimus: a clinical case and review of the literature.Safety of eribulin mesylate and concomitant radiotherapy for metastatic breast cancer: a single-center experience.Treatment of invasive male breast cancer: a 40-year single-institution experience.Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer.Oral Lapacho-Based Medication: An Easy, Safe, and Feasible Support to Prevent and/or Reduce Oral Mucositis During Radiotherapy for Head and Neck Cancer.Prognostic factors in patients with locally advanced head and neck cancer treated with concurrent radiochemotherapy.Soft tissue myxofibrosarcoma: A clinico-pathological analysis of a series of 75 patients with emphasis on the epithelioid variant.Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial.Reirradiation in head and neck recurrent or second primary tumor: efficacy, safety, and prognostic factors.Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer.Clinical outcome of stereotactic body radiotherapy for abdominal lymph node metastases.Impact of sentinel node tumor burden on outcome of invasive breast cancer patients.Neoadjuvant treatment of soft tissue sarcoma.Atypical and malignant meningioma: outcome and prognostic factors in 68 irradiated patients.Neoadjuvant oxaliplatin and 5-fluorouracil with concurrent radiotherapy in patients with locally advanced rectal cancer: a single-institution experience.P13.22CYBERKNIFE STEREOTACTIC RADIOSURGERY FOR THE RE-IRRADIATION OF BRAIN LESIONS: A SINGLE-CENTRE EXPERIENCE.O7.02RADIOSURGERY AND BRAIN METASTASES: ADEQUATE SEQUENCE OF BRAIN MRI CAN SIGNIFICANTLY CHANGE THE INTRACRANIAL DISEASE STAGING.Application of helical tomotherapy for the treatment of a right atrium angiosarcoma: a case report.P06.13OUTCOME AND PROGNOSTIC FACTORS IN ATYPICAL AND MALIGNANT MENINGIOMA: UNIVERSITY OF FLORENCE EXPERIENCE.P13.21ORGANS AT RISK IN THE BRAIN AND THEIR DOSE-CONSTRAINTS IN THE ADULTS AND IN THE CHILDREN: A RADIATION ONCOLOGIST'S GUIDE FOR DELINEATION.Organs at risk in the brain and their dose-constraints in adults and in children: a radiation oncologist's guide for delineation in everyday practice.Cyberknife stereotactic radiosurgery for the re-irradiation of brain lesions: a single-centre experience.Impact of a breathing-control system on target margins and normal-tissue sparing in the treatment of lung cancer: experience at the radiotherapy unit of Florence University.Stereotactic body radiotherapy for cardiac and paracardiac metastases: University of Florence experience.Role of radiotherapy boost in women with ductal carcinoma in situ: a single-center experience in a series of 389 patients.Stereotactic body radiotherapy with CyberKnife for cardiac malignancies.Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen.Protective Effect of Leuprorelin on Radiation-induced Intestinal Toxicity.The PEDRO (Pocketable Electronic Devices in Radiation Oncology) project: how clinical practice is changing among young radiation oncologists.Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the Italian young radiation oncologist meeting.Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience.
P50
Q30248531-005EB2BD-3B5A-43D6-A8AF-21648A6524DBQ33442985-851E18E6-8E80-4147-83CF-A8B58391C545Q33876719-07209FB4-A679-43BC-9E4D-634B223CA2B9Q35885609-827AC085-D63A-4E29-828C-80D3B944F992Q37937326-AEC24502-0C91-491E-A3FA-AFA05050A642Q38008092-D99366BC-D272-4589-82B1-E661BB10D386Q38115170-57EE2E03-BDA7-4682-AC2E-61A67E2AC539Q38226822-005E0F2C-CC42-4D03-B3D5-977D1EF885E4Q38801239-33947EA3-372A-49AC-B958-075BE546B289Q38885327-66A858E8-074D-41B4-9120-AF9E7A0C6667Q38897959-64DD09A3-62A1-413D-B2D4-27C140DC1F8BQ39572831-7B71E8C7-02F5-47CA-837A-56A1543AF596Q39693600-B9329661-423E-4859-A382-347F1780B1C8Q40449052-02931B25-86E8-4C8B-8EE3-F9D2DC159B96Q40505371-84559157-BC31-4038-B7CB-C95F763AB964Q40801723-577F5106-FF27-411C-B39A-AC9688C7EAE9Q41387966-BCC5E84F-39BF-413D-82F6-B27A3EFE786BQ41644218-BC793E37-96C5-4EA6-B394-53AD3D1C9F7CQ43236882-ED608F56-A2F7-496B-80BC-C8BFA9BE5E2BQ43458062-BBD510CC-CB6C-4AEA-97C7-1DCE2F21F98BQ43587647-ECC374FA-1BD1-4A43-83B2-931CF8E423C9Q43709885-94E129DF-23C1-4732-B7A9-4DBDC36FC5DFQ44596691-7DC9F76F-D7DB-442C-A7C6-5E3D9D885ED6Q44948248-F31956BD-0C64-4519-8A51-75A2703330C7Q46044376-8CB0CE50-0BB5-45A2-998D-7F291332EB0FQ46274937-36F782D3-65FF-4B43-9095-5450CD7E7EC4Q46551199-F8B4A31A-5CA5-4B65-90C0-FE0B97078E77Q46881718-044F78A1-1345-4C5B-8E21-93AE02DAE080Q46883362-6EB72E4A-DEB6-472B-936E-FBC2E979AA1CQ48318268-2411CBFA-36FA-48EC-B767-F1D553811E9EQ50728750-652DD426-F67F-47C8-8C0B-E60C68278D7DQ50753662-A41D330E-5423-488D-BD74-0974DCE8771DQ50851277-824B5015-4AE3-4F99-BBFA-68506991106EQ50864302-9E283A67-1B4F-41CA-87A6-744EA0BA49C7Q50926119-82392FD3-50DF-41DA-80AA-CE5CF425EF72Q50985005-18FF3D85-4C26-49A7-AAB9-229DDAEE5D44Q51011197-D45B354C-CF6F-485A-9610-B518F427244BQ53311532-DE95E5CE-32F9-48BF-8E4D-2084B50F47CEQ54312389-89774F98-7E5A-4FAB-99B8-252B734E1B8BQ54459895-47EC6EFC-609B-4A99-8509-6F5FC6B473C5
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Daniela Greto
@en
Daniela Greto
@nl
type
label
Daniela Greto
@en
Daniela Greto
@nl
prefLabel
Daniela Greto
@en
Daniela Greto
@nl
P31
P496
0000-0002-2667-0841